Evidence map›Paper›PMID 16627760›Full record

ArticleBlood2006

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Christian Flotho, Elaine Coustan-Smith, Deqing Pei, Shotaro Iwamoto, Guangchun Song, Cheng Cheng, Ching-Hon Pui, James R Downing, Dario Campana

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
NCT00187005 phase3terminatednot on this map

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan1998 to 2002Enrolled53ConditionsAcute Lymphoblastic LeukemiaArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase, L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Review
  3. Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Transcription factor E2F3a regulatesCancer cell international · 2018
    Article
  15. Low miR-210 andOncology letters · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christian FlothoDepartment of Pathology, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA.
Elaine Coustan-Smith
Deqing Pei
Shotaro Iwamoto
Guangchun Song
Cheng Cheng
Ching-Hon Pui
James R Downing
Dario Campana
University of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
DETECTION AND THERAPY OF RESIDUAL LEUKEMIA IN CHILDRENR01CA060419 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CAMPANA, DARIO · 1998 to 2006
$1.7M
DETECTION OF MINIMAL RESIDUAL LEUKEMIA IN CHILDRENU01CA060419 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CAMPANA, DARIO · 1993 to 1996
–
NCI NIH HHS CA21765NCI NIH HHS CA60419
6 · The paper itself

Abstract

In childhood acute lymphoblastic leukemia (ALL), early response to treatment is a powerful prognostic indicator. To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment. After excluding genes associated with genetic subgroups, we identified 17 genes that were significantly associated with MRD. The caspase 8-associated protein 2 (CASP8AP2) gene was studied further because of its reported role in apoptosis and glucocorticoid signaling. In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD, low levels of CASP8AP2 expression predicted a lower event-free survival (P = .02) and a higher rate of leukemia relapse (P = .01) and were an independent predictor of outcome. High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis. We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy. Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis.

Indexed as

Predictive Value of TestsAdolescentApoptosisApoptosis Regulatory ProteinsCalcium-Binding ProteinsChildChild, PreschoolDisease-Free SurvivalFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInfantMaleNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaApoptosis Regulatory ProteinsCalcium-Binding ProteinsCASP8AP2 protein, human

Identifiers

PMID16627760
PMCPMC1895863
OpenAlexW2007491213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.